Trial of high-dose XXXX , @entity786 , @entity348 , and autologous marrow transplantation for @entity706 .

@entity1 @entity137 @entity401 @entity706 @entity5 @entity786 @entity2592 @entity348 @entity1893 @entity978
Twenty-one @entity1 with advanced @entity1893 or @entity978 who had failed to be cured with standard therapy were the subjects of this clinical trial. The @entity1 received @entity2592 (3 g/m2 at 12-hour intervals for six or eight doses), @entity786 (90 mg/kg once), and @entity348 (one 900-cGy fraction or five 250-cGy fractions). Bone marrow was aspirated and cryopreserved before treatment and reinfused after the completion of radiotherapy. Eighteen @entity1 (86%) had objective response and 12 (57%) achieved complete response. Three @entity1 remain in continuous complete remission for 566+, 604+, and 1035+ days after marrow infusion. Six complete responders had @entity5 recurrence. One of these @entity1 developed a @entity706 of another histology that was successfully treated with local radiotherapy and the @entity1 is currently well 1004+ days after marrow infusion. Another relapsing @entity1 responded to a brief course of salvage chemotherapy and is in remission at 1271+ days. Three of the complete responders died from infectious complications. This regimen was associated with significant @entity137 . Six @entity1 died from sepsis during the period of aplasia and three others died from @entity401 42-105 days after marrow infusion. Although this regimen demonstrated a high level of antitumor activity, the value of adding high-dose @entity2592 to the combination of @entity786 and @entity348 remains unclear and would require a randomized clinical trial to demonstrate.
